Targeted Oncology

Phase 3 Trial of T-DXd Initiated in HER2+ Endometrial Cancer

DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...
Medscape

T-DXd Wins First-Line Indication for HER2+ Breast Cancer

FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or ...
Targeted Oncology

FDA Grants Breakthrough Therapy Designation to T-DXd Early HER2+ BC

The FDA has granted breakthrough therapy designation (BTD) to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the ...
Oncology Nurse Advisor

T-DXd Redefines Post-Neoadjuvant Therapy in HER2+ Breast Cancer

Trastuzumab deruxtecan continues to demonstrate superior safety and efficacy compared with trastuzumab emtansine in patients with high-risk, HER2-positive early breast cancer who have residual ...
The American Journal of Managed Care

T-DXd Regimens Show Better Tolerability, Manageable Safety in High-Risk, HER2-Positive Early Breast Cancer

T-DXd regimens improved pathologic complete response and safety profiles compared to ddAC-THP in high-risk, HER2-positive early breast cancer. Patient-reported outcomes showed better physical ...
Nasdaq

Daiichi Sankyo Showcases Progress in Developing New Standards of Care for Patients with Industry-Leading DXd ADC Portfolio Across Multiple Cancers at ESMO

Three late-breaking abstracts, including two Presidential Symposia presentations, showcase datopotamab deruxtecan data from TROPION-Breast01 and TROPION-Lung01 phase 3 trials New data featuring first ...
ascopubs.org

Comparing clinical benefit of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in a large cohort of HER2-negative metastatic breast cancer (MBC).

Use of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and CDK4/6 inhibitor (CDK4/6i) therapy (tx) and to analyze intrinsic vs acquired endocrine resistance ...